RxDoctor Payments Data

Silke Hoosier

Family · Kimball, TNNPI 1881133643

Payments from drug & device makers

$2,305in general payments, 2019–2025

Across 127 payments — averaging $18.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$713
  • Lilly USA, LLC$323
  • Bayer$207
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$203
  • AbbVie$131
  • Pfizer$107
  • plus $620 from 11 others

What the payments were for

  • Food & beverage$2,305100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,305 in reported general payments places this provider in the 75th percentile of 6,706 family providers in Tennessee.

See all family providers in Tennessee

Medicare billing

Part B allowed, 2024
$28,180
Medicare patients
104
Services billed
627

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide110$114,568
MounjaroTirzepatide45$63,932
Trelegy ElliptaFluticasone/Umeclidin/Vilanter59$44,994
EliquisApixaban42$43,518
JardianceEmpagliflozin33$38,242
FarxigaDapagliflozin Propanediol38$37,665
MyrbetriqMirabegron37$29,743
BelsomraSuvorexant53$21,887
RybelsusSemaglutide19$21,453
Breztri AerosphereBudesonide/Glycopyr/Formoterol30$19,661
XareltoRivaroxaban14$15,319
Nurtec OdtRimegepant Sulfate14$13,163
Breo ElliptaFluticasone/Vilanterol18$11,276
ShingrixVaricella-Zoster Ge/As01b/Pf40$8,821
LinzessLinaclotide11$8,509

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$713$136,021129 claims
GSKTrelegy Ellipta, Breo Ellipta, Shingrix, Arexvy$55$69,373131 claims
Lilly USA, LLCMounjaro$323$63,93245 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$63$60,46881 claims
PfizerEliquis, Nurtec Odt$107$56,68156 claims
Johnson & JohnsonXarelto$40$15,31914 claims
AbbVieLinzess, Synthroid$131$9,68346 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 6,706 family providers in Tennessee.

Other family in Kimball

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →